Myasthenia Gravis and Related Disorders

Häftad, Engelska, 2018

1 219 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

The overarching goal of this new edition is identical to the first and second -- to provide the clinician and the scientist with a common resource for understanding the profound achievements in the clinical, translational, and basic sciences of neuromuscular transmission disorders.

Produktinformation

Utgivningsdatum2018-12-22
Mått178 x 254 x 19 mm
Vikt786 g
FormatHäftad
SpråkEngelska
SerieCurrent Clinical Neurology
Antal sidor353
Upplaga3
FörlagSpringer Nature Switzerland AG
ISBN9783030088156

Tillhör följande kategorier

Onkologi inom Medicin
Lungmedicin inom Medicin
Biovetenskap inom Naturvetenskap och teknik
Neurologi och klinisk neurofysiologi inom Medicin

Chapter 1. Neuromuscular Junction Physiology and Pathophysiology.- Chapter 2. Acetylcholine Receptor Structure.- Chapter 3. Immunopathogenesis of Myasthenia Gravis.- Chapter 4. Animal Models of Myasthenia Gravis for Preclinical Evaluation.- Chapter 5. Epidemiology and Genetics of Myasthenia Gravis.- Chapter 6. Clinical Presentations of Myasthenia Gravis.- Chapter 7. Ocular Myasthenia.- Chapter 8. Thymoma-associated Myasthenia Gravis.- Chapter 9. Electrodiagnosis of Neuromuscular Junction Disorders.- Chapter 10. Autoantibody Testing in the Diagnosis and Management of Autoimmune Disorders of Neuromuscular Transmission and Related Diseases.- Chapter 11. Treatment of Myasthenia Gravis.- Chapter 12. Neurocritical Care of Myasthenic Crisis.- Chapter 13. Thymectomy for Non-thymomatous Myasthenia Gravis.- Chapter 14. Lambert-Eaton Syndrome.- Chapter 15 Acquired Neuromyotonia.- Chapter 16. Congenital Myasthenic Syndromes.- Chapter 17. Toxic Neuromuscular Transmission Disorders.- Chapter18. Predictors of Psychological Health in Myasthenia Gravis.- Chapter 19. Myasthenia Gravis: Classification and Outcome Measurements.- Chapter 20. Emerging Therapeutics for Myasthenia Gravis.- Chapter 21. Clinical Trial Design for Myasthenia Gravis.